US THROMBOTIC MICROANGIOPATHY ALLIANCE (EIN 831768842) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2018

Legal Domicile

Principal Officer

CLARE MARTIN

Phone

6149994900

Tax Period

2024-01-01 to 2024-12-31

US THROMBOTIC MICROANGIOPATHY ALLIANCE, founded in 2018, is a small nonprofit in the Diseases & Disorders sector that reported $595K in total revenue in fiscal year 2024. Revenue fell 68% from the prior year — a significant decline worth monitoring. Expenses of $790K exceeded revenue, resulting in a 33% operating deficit.

Mission

TO IMPROVE OUTCOMES FOR PATIENTS WITH THROMBOTIC MICROANGIOPATHY THROUGH COLLABORATION AND ADVOCACY

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $241,034

Program Service Revenue $564,124

Investment Income $79,457

Other Revenue $-289,121

TOTAL REVENUE $595,494

Expense Breakdown

Grants Paid $0

Salaries & Benefits $211,882

Fundraising Expenses $0

Program Expenses $255,397

Other Expenses $577,683

TOTAL EXPENSES $789,565

Year-over-Year Comparison

	2024	2023	Change
Revenue	$595,494	$1,860,040	-0.7%
Expenses	$789,565	$669,026	+0.2%
Net Income	$-194,071	$1,191,014	-1.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

$136,772

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARSHALL MAZEPA	MEDICAL DIRE	N/A	Director	$0	$0	$0
SHRUTI CHATURVEDI	MEDICAL DIRE	N/A	Director	$0	$0	$0
CLARE MARTIN	OPERATIONS D	40.00	Director	$136,772	$0	$136,772
ARA METJIAN	MEDICAL DIRE	N/A	Director	$0	$0	$0
SATHEESH CHONAT	MEDICAL DIRE	N/A	Director	$0	$0	$0
SPERO CATALAND	MEDICAL DIRE	N/A	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$595,494	$789,565	$1,823,162	$-194,071
2023	$1,860,040	$669,026	$2,053,500	$1,191,014
2022	$950,114	$300,712	$797,343	$649,402

US THROMBOTIC MICROANGIOPATHY ALLIANCE